The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2-associated metastatic HER2-negative breast cancer (BC).
 
Filipa Lynce
Leadership - Alliance Foundation Trials
Consulting or Advisory Role - AmerisourceBergen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Pfizer; Prime Education
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences; IDEAYA Biosciences; Incyte; Merck; Zentalis
 
Adela Rodriguez Hernandez
Travel, Accommodations, Expenses - AstraZeneca Spain; MSD Oncology
 
Siddhartha Yadav
Consulting or Advisory Role - AstraZeneca (Inst)
Research Funding - AstraZeneca (Inst); REPARE Therapeutics (Inst)
 
Ryan Buehler
No Relationships to Disclose
 
Grace Augdahl
No Relationships to Disclose
 
Tasnim Rahman
No Relationships to Disclose
 
Michelle DeMeo
No Relationships to Disclose
 
Adrienne Waks
Consulting or Advisory Role - AstraZeneca
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Macrogenics (Inst); Merck (Inst)
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Nadine Tung
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst)
 
Judy Garber
Consulting or Advisory Role - Belharra Therapeutics, Inc. (I); Earli, Inc.; GV20 Therapeutics (I); Kronos Bio (I); Novartis (I)
Research Funding - Ambry Genetics; Amgen; InVitae; Novartis (I)
Other Relationship - Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Facing our Risk of Cancer Empowered; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation (I)
 
Nabihah Tayob
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018
 
Jennifer Guerriero
No Relationships to Disclose